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ABSTRACT
Optic neuropathies such as glaucoma occur when retinal ganglion cells (RGCs) in the eye are
injured. Strong evidence suggests mesenchymal stem cells (MSCs) could be a potential therapy to
protect RGCs; however, little is known regarding their effect on the human retina. We, therefore,
investigated if human MSCs (hMSCs), or platelet-derived growth factor (PDGF) as produced by
hMSC, could delay RGC death in a human retinal explant model of optic nerve injury. Our results
showed hMSCs and the secreted growth factor PDGF-AB could substantially reduce human RGC
loss and apoptosis following axotomy. The neuroprotective pathways AKT, ERK, and STAT3 were
activated in the retina shortly after treatments with labeling seen in the RGC layer. A dose depen-
dent protective effect of PDGF-AB was observed in human retinal explants but protection was not
as substantial as that achieved by culturing hMSCs on the retina surface which resulted in RGC cell
counts similar to those immediately post dissection. These results demonstrate that hMSCs and
PDGF have strong neuroprotective action on human RGCs and may offer a translatable, therapeutic
strategy to reduce degenerative visual loss. STEM CELLS 2018;36:65–78
SIGNIFICANCE STATEMENT
Stem cell therapies that work in rodent models are frequently proposed as potential treat-
ments for human disease. Testing of such strategies in human tissue is an important interim
between preclinical and clinical studies. Results of this study show that human mesenchymal
stem cells and platelet-derived growth factor provide significant protection to cells of the
human retina, supporting observations seen in rodent models of optic nerve injury. This work
highlights that similar, although not identical, mechanisms are responsible for retinal protection
and that future stem cell-based treatments may have the potential to reduce visual
deterioration.
INTRODUCTION
There has been considerable recent interest in
the potential use of stem cells to treat a vari-
ety of neurodegenerative diseases. We and
others have previously shown that injection of
mesenchymal stem cells (MSCs) into the eye
can signiﬁcantly delay retinal ganglion cell
(RGC) death in models of glaucoma and optic
nerve injury [1–6]. Using a rat ex vivo retinal
explant system, we demonstrated that much
of the neuroprotective effect of MSCs was
mediated by platelet-derived growth factor
(PDGF), a family of growth factors not previ-
ously associated with RGC survival in glaucoma
[7]. We also showed PDGF could preserve RGC
synaptic proteins in vivo [8] and minimize axo-
nal loss within the optic nerve in experimen-
tally induced ocular hypertension [7],
supporting further investigation of PDGF treat-
ment as a potential future glaucoma therapy.
However, to date, no such studies have
examined the translatability of these experi-
ments to the human retina. Species differences
in pathogenic and therapeutic pathways are
conceivable [9] and may contribute to the poor
rate of successful translation of treatment strat-
egies from animal models to human clinical tri-
als [10–12]. Although the preclinical assessment
of human RGC neuroprotection has proven chal-
lenging (partly due to the limitations of available
animal models as well as tissue availability and
difﬁculties in the culture of adult human RGCs),
ex vivo retinal explants can provide a useful
model to study some aspects of retinal disease
[13–15]. Importantly, we have shown good cor-
relation between the ability of therapies to pro-
tect RGCs in explants and in vivo models of
experimental glaucoma [16].
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REGENERATIVE MEDICINE
In the current study, we aimed to determine if human
MSCs (hMSCs) or PDGF could reduce RGC loss and apoptosis
in the human retina. By investigating the downstream signal-
ing pathways following treatments, we also set out to clarify
the mechanisms involved in human RGC neuroprotection and
the impact of pathway inhibition. Through understanding the
role of hMSC and hMSC-derived factors on human tissue, we
hope to accelerate and support future therapies to prevent
visual deterioration.
MATERIALS AND METHODS
Human Retinal Explant Culture
Donor human eyes were obtained <24 hours post-mortem
from the East Anglian Eye Bank (Norfolk and Norwich Univer-
sity Hospital) with research being conducted under the tenets
of the Declaration of Helsinki with ethical approval from the
U.K. National Research Ethics Committee (REC 04/Q0102/57
and REC 11/EE/0112). All donated eyes were free of diag-
nosed retinal pathology and contained no evidence of ocular
trauma or retinal injury. In total, 34 human post-mortem eye
globes from 17 donors aged 36 to 78 years (Supporting Infor-
mation Fig. 1C) were used for this study.
Human retinal explants were excised and cultured through
a combination of previously published methods [13–15]. The
anterior portion of each donor eye was removed and the
intact retina detached from the retinal pigmented epithelium
via cuts around the ciliary body and at the optic nerve head.
A ﬂat retinal preparation was created and the macula
removed using a 4-mm diameter dissecting trephine (Biomedi-
cal Research Instruments, MD). Six smaller 3-mm circular
explants were taken equidistant from the macula in regions of
comparable RGC number [14, 15] (Supporting Information Fig.
1A, 1B). Explants were cultured, photoreceptor side down, on
polytetraﬂuoroethylene membranes (EMD Millipore, Billerica,
MA) in 300 ll Neurobasal-A media containing 2% B27 supple-
ment, 1% N2 supplement, L-glutamine (0.8 mM), penicillin
(100 U/ml) and streptomycin (100 mg/ml) (All from Invitro-
gen, Paisley, U.K.) at an air-ﬂuid interface in 12 well plates
(Corning, NY).
The six explants from a single retina represent an experi-
mental (n) of 1, with each explant receiving a separate treat-
ment as illustrated at the top of ﬁgures. This ensures all
groups are age and donor matched to limit variation. Some-
times only four of the six explants were used in an experi-
ment where certain explants were not deemed of good
enough quality to include in the study or were used for other,
unrelated experiments. Explants were cultured for up to 7
days ex vivo (7DEV) at 358C in a humidiﬁed atmosphere of
95% air/5% CO2. Medium was either unchanged throughout
experiments or, where stated, half the medium was replen-
ished daily.
Retinal explants were treated with recombinant human
PDGF-AA or -AB (#100-13A and 100-00AB, Peprotech, Rocky
Hill, NJ), and/or inhibitors of molecular signaling pathways,
added to the culture medium at the beginning of experi-
ments. A selection of explants were cocultured with hMSCs,
added as a bolus 5 ml droplet of 5,000 cells to the RGC layer
shortly after dissection. Inhibitors of PDGF and its down-
stream signaling pathways included PDGF neutralizing
antibody (35 mg/ml; EMD Millipore, Billerica, MA), the phos-
phatidylinositol 3 (PI3) kinase inhibitor LY294002 (75 mM; Cell
Signaling Technology, Danvers, MA), the ERK inhibitor U0126
(50 mM; Promega, Southampton, U.K.) and the STAT3 inhibitor
S3I-201 (100 mM; Sigma-Aldrich, Poole, U.K.).
hMSCs Culture
hMSCs were purchased from Stem Cell Technologies and cul-
tured in DMEM (1 g/l glucose; Invitrogen, Paisley, U.K.) con-
taining 10% fetal bovine serum (Invitrogen, Paisley, U.K.), and
1% penicillin and streptomycin (Thermo Scientiﬁc, Loughbor-
ough, U.K.). Cells were expanded from the same stocks as we
have used previously [7] whereby the vendor had shown a
>90% expression of CD29, CD44, CD105, and CD166 and
<1% expression of CD14, CD34, and CD45. hMSCs were split
at 75%–90% conﬂuence and used between passages 9 and
14. For transplantation studies, hMSCs expression of the mes-
enchymal markers CD105 and CD73 was veriﬁed (Supporting
Information Fig. 1D) and the cells were resuspended in
explant medium prior to culture on the RGC layer of the ret-
ina. For conditioned medium investigation, hMSCs were
grown in T75 tissue culture ﬂasks (Corning, NY) and trans-
ferred to serum free medium for 72 hours.
Immunohistochemistry and TUNEL Analysis
Immunohistochemistry was used to quantify the survival of
RGC layer cell populations as previously demonstrated
[14–16] and to visualize the activation and location of the
PDGF receptors and their downstream signaling pathways
within the retina. Explants were ﬁxed in 4% paraformaldehyde
(24 hours), cryopreserved in a 30% sucrose solution in PBS at
48C (24 hours) before 13 lm sections were collected using a
Bright OTF 5000 cryostat (Bright Instruments, Huntingdon,
U.K.). Antigen retrieval (incubation for 5 minutes at 808C in
10 mM Sodium Citrate Buffer, 0.05% Tween 20, pH 6.0) or
methanol permeabilization (submersion for 5 minutes in ice
cold 100% methanol) were used to enhance epitope-antibody
binding for phosphorylated and total PDGF receptors, MSC
markers and phosphorylated-STAT3 antibodies prior to block-
ing. Transverse sections were simultaneously blocked and per-
meabilized by incubation in 5% normal goat serum in PBS
with 0.3% Triton X-100 for 1 hour at room temperature.
Sections were incubated in primary antibody (Supporting
Information Table 1) diluted in blocking solution overnight at
48C, before incubation with secondary antibody diluted in
blocking solution for 2 hours at room temperature. Nuclei
were counterstained with DAPI.
The DeadEnd Fluorometric TUNEL system (TUNEL) (G3250
Promega, Southampton, U.K.) was performed alongside NeuN
immunohistochemistry to visualize apoptotic RGCs. TUNEL
staining was carried out in between primary and secondary
antibody steps according to manufacturer’s instructions and
as previously performed [15]. Samples were then mounted
with ﬂuorSave reagent (Calbiochem/EMD Chemicals Inc.,
Gibbstown, NJ) prior to imaging.
DAPI1, NeuN1, and TUJ11 cell densities within the RGC
layer were quantiﬁed by a masked investigator in at least
eight sections per explant using a 320 objective and a Leica
DM6000 epiﬂuorescence microscope (Leica Microsystems,
Wetzlar, Germany). NeuN1 cells which also stained positive
for TUNEL were identiﬁed as apoptotic RGCs. Visualization of
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PDGFR activation and downstream signaling were assessed
using a Leica SP5 confocal microscope (Leica Microsystems,
Wetzlar, Germany) equipped with a 340 oil objective using a
31.5 digital zoom and 0.5–0.8 sequential scanning z-step
interval.
Western Blotting
Protein extraction was performed by lysing explants in Mamma-
lian Protein Extract Reagent M-PER supplemented with Halt
Phosphatase Inhibitor Cocktail, Protease Inhibitor Cocktail and
5 mM EDTA (All from Thermo Scientiﬁc, Loughborough, U.K.). Tis-
sue was homogenized on ice for 20 minutes and then centrifuged
at 13,000 rpm for 5 minutes to isolate the soluble cell extract.
Protein concentration was determined using a bicinchoninic acid
protein assay (Thermo Scientiﬁc, Loughborough, U.K.).
Ten micrograms of protein was loaded into 4%–12% precast
gels and electro-transferred to polyvinylidene diﬂuoride (PVDF)
membranes (Thermo Scientiﬁc, Loughborough, U.K.). Membranes
were blocked in 5% dried skimmed milk in PBS with 0.2%
Tween20 (Sigma-Aldrich, Poole, U.K.) for 1 hour and incubated
overnight with primary antibody (Supporting Information Table 1)
in blocking solution at 48C. Horseradish peroxidase (HRP) conju-
gated secondary antibodies (1:10,000, Vector Laboratories Ltd.,
Peterborough, U.K.) were used for 2 hours before signal detection
using ECL Prime (Amersham, GE Healthcare, U.K.) and an Alliance
Western blot imaging system (UVItec Ltd., Cambridge, U.K.).
Proteome Profiler Arrays
hMSCs conditioned media were concentrated 10–153 using
Amicon Ultra-15 centrifugal ﬁlter units (EMD Millipore, Biller-
ica, MA) prior to analysis using commercially available human
angiogenesis proteome proﬁler arrays (R&D systems, Abing-
don, U.K.) according to the manufacturer’s instructions. Mem-
branes were developed using ECL Prime and a UVItec imaging
system with antibody spot integrated density quantiﬁed using
ImageJ.
Lactate Dehydrogenase Assay
The level of necrotic cell damage was determined by measur-
ing the lactate dehydrogenase (LDH) activity in treated cell
culture medium according to the manufacturer’s instructions
(Roche Molecular Biochemicals, Burgess Hill, U.K.).
ELISA
Human PDGF-AB ELISA arrays (Roche Molecular Biochemicals,
Burgess Hill, U.K.) were used to measure PDGF degradation in
experiments.
Statistical Analysis
Data are presented as the mean6 standard error of the mean
(s.e.m) for all bar charts and scatter plots, with (n) represent-
ing the number of completely independent experiments per-
formed on separate retinas. Comparisons between two
groups were made using two-tailed unpaired Student’s t tests.
Comparisons between three or more groups were made with
one-way ANOVA with Dunnett’s post hoc test (GraphPad
Prism; Graph-Pad Software Inc., La Jolla, Ca) to compare
experimental groups to controls if p< .05.
RESULTS
Protection of Human RGCs by PDGF and hMSC
Treatments
Our previous work has demonstrated that MSCs can delay
loss of axotomized RGCs in rodent retinal explants [16], with
secreted PDGF playing a signiﬁcant role in prolonging RGC
survival [7]. The current work expanded on those experiments
by examining whether neuroprotection could also be demon-
strated in a human retinal explant system. RGC number
immediately post dissection, 0 days ex vivo (0DEV), provided
an indication of the maximum number of surviving RGCs
within explants. Over 7 days culture (7DEV) in control condi-
tions, retinal thickness (Supporting Information Fig. 2A–2D)
and the number of RGC layer cells decreased (Fig. 1A–1F).
However, regular treatment of 50 ng/ml PDGF-AB or -AA1AB
could attenuate retinal thinning and RGC loss. Treatment of
explants with PDGF-AB increased the survival of both DAPI1
(99.26 2.4 vs. 74.56 7.2 cells/mm, p< .05, Fig. 1A, 1E) and
NeuN1 neurons (30.96 1.2 vs. 19.46 2.4 cells/mm, p< .05,
Fig. 1B, 1E) in the RGC layer compared with untreated
explants (7DEV Control). Similarly, treatment with PDGF-
AA1AB protected RGC number (DAPI, 92.96 9.3 vs.
74.56 7.2 cells/mm, NeuN, 34.36 6.6 vs. 19.46 2.4 cells/
mm, p< .05, Fig. 1A, 1B, 1E) compared with same day con-
trols (7DEV Control). Quantiﬁcation of TUJ11 neurons in the
RGC layer also demonstrated a comparable level of neuropro-
tection, although statistical signiﬁcance was not reached with
PDGF-AB treatment (21.76 1.8 vs. 15.76 2.1 cells/mm,
p5 .070, Fig. 1C, 1F).
Even greater protection could be seen in explants cocul-
tured with hMSCs compared with controls (DAPI, 109.26 15.1
vs. 74.56 7.2 cells/mm, NeuN, 42.66 9.9 vs. 19.46 2.4 cells/
mm, TUJ1, 33.96 8.4 vs. 15.76 2.1 cells/mm, p< .05, Fig.
1A–1C, 1E, 1F) with a doubling in the number of surviving
RGCs after 7 days and RGC counts that were similar to those
measured immediately after dissection (0DEV Control).
Assessment of the apoptotic status of remaining RGC layer
cells after 7 days revealed 33.0%6 4.4% were apoptotic with
PDGF-AB treatment, 39.9%6 4.8% with PDGF-AA1AB and
31.5%6 2.9% with hMSC coculture (Fig. 1D, 1E). Untreated
explants at 7 days exhibited signiﬁcantly greater levels of cell
death with 51.9%6 3.4% of remaining RGCs staining TUNEL
positive. Of note, PDGF-AA alone did not offer signiﬁcant pro-
tection against cell loss nor apoptosis compared with
untreated explants (Fig. 1A–1F).
Effectiveness of a Single Treatment of PDGF-AB on
RGC Survival at 7 Days’ Ex Vivo
We had previously not investigated ex vivo whether a single
treatment with PDGF, as would be desirable in a human ther-
apy, could mitigate RGC loss. A single supplement of 50 ng/ml
PDGF-AB added at day 0 offered minimal protection over the
7-day time period, with marginally increased cell numbers
compared with same time point controls (DAPI, 66.96 5.5 vs.
60.06 5.4 cells/mm, NeuN, 17.96 1.9 vs. 12.76 0.6 cells/mm,
TUJ1 14.76 1.6 vs. 13.16 1.3 cells/mm, Fig. 2A–2C, 2E, 2G).
Apoptosis was also slightly reduced but did not reach signiﬁ-
cance (7DEV PDGF-AB (50 ng/ml), 53.5%6 3.1% vs. 7DEV Con-
trol, 58.0%6 2.8%, p5 .348, Fig. 2D–2F). However, a higher
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concentration of PDGF-AB (150 ng/ml) increased RGC layer
survival (DAPI, 72.46 3.0 vs. 60.06 5.4 cells/mm, NeuN,
25.36 3.1 vs. 12.76 0.6 cells/mm, TUJ1, 18.76 1.4 vs.
13.16 1.3 cells/mm, p< .05, Fig. 2A–2C, 2E) and limited
neuronal death (7DEV PDGF-AB [150 ng/ml], 40.6%6 3.7% vs.
7DEV Control, 58.0%6 2.9%, p< .01, Fig. 2A–2G). Again, cocul-
turing hMSCs on top of explants, even in the absence
of medium changes, offered the greatest protection to RGCs in
Figure 1. Human RGC neuroprotection by PDGF or human MSCs following regular medium replenishment. Human retinal explants
were cultured for 7 days in medium containing PDGF or with the addition of hMSCs pipetted directly onto the RGC layer surface. (A–C):
Neuronal survival in the RGC layer was quantiﬁed immediately post dissection, 0DEV or after 7 days’ culture (7DEV) (n5 6). (D): Number
of apoptotic, NeuN1 cells were quantiﬁed and expressed as a percentage of all NeuN1 cells in the RGC layer (n5 6). (E, F): Representa-
tive images of RGCs (NeuN - green or TUJ1 - blue) in human retinal explants with apoptotic cells labeled red. 320 objective, scale
bar5 50 mm, *, p< .05; **, p< .01; ***, p< .001. Bar and scatter graphs show mean6 s.e.m with (n) number indicating the number
of unique post-mortem eyes used. The schematic in the top left shows the number of explants processed from each retina and the
treatment time course. Abbreviations: 0DEV, 0 days ex vivo; 7DEV, 7 days ex vivo; MSC, mesenchymal stem cell; PDGF, platelet-derived
growth factor; RGCL, retinal ganglion cell layer.
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Figure 2. Human RGC neuroprotection after a single treatment of PDGF or human MSCs. Human retinal explants were cultured for 7
days in medium containing PDGF or with the addition of hMSCs pipetted directly onto the RGC layer surface. (A–C): Neuronal survival
in the RGC layer was quantiﬁed immediately post dissection, 0DEV or after 7 days’ culture with no further medium change (7DEV)
(n5 6) (D): Number of apoptotic, NeuN1 cells were quantiﬁed and expressed as a percentage of all NeuN1 cells in the RGC layer
(n5 6). (E, F): Magniﬁed, representative images of RGCs (NeuN - green or TUJ1 - blue) in human retinal explants with apoptotic cells
labeled red. 340 objective, scale bar5 50 mm, *, p< .05, **, p< .01 and ***, p< .001. Bar and scatter graphs show mean6 s.e.m with
(n) number indicating the number of unique post-mortem eyes used. The schematic in the top left shows the number of explants proc-
essed from each retina and the treatment time course. Abbreviations: 0DEV, 0 days ex vivo; 7DEV, 7 days ex vivo; MSC, mesenchymal
stem cell; PDGF, platelet-derived growth factor; RGCL, retinal ganglion cell layer.
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terms of both cell number and reducing apoptosis (Fig. 2A–
2G).
Sampling of the unchanged culture medium also revealed
a steady increase in retinal tissue necrosis over time for all
treatments. The rate of necrotic cell death was greatest in cul-
ture medium taken from untreated explants (Control,
0.956 0.13 necrotic units per day) with reduced necrosis
noted from 150 ng/ml PDGF-AB or hMSC-treated explants
(respective 0.556 0.32 and 0.786 0.18 necrotic units per day,
p< .05, Fig. 3A).
Assessment of PDGF-AB concentration in the bathing
medium at 1, 3, and 5 days provided a measure of PDGF utili-
zation/degradation by retinal tissue. Initial sampling conﬁrmed
the correct concentration of PDGF-AB had been administered
to explants and levels approximately halved after 1 day in
culture (0DEV PDGF-AB [150 ng/ml], 1496 3.8 vs. 1DEV
PDGF-AB [150 ng/ml] 71.696 16.4 ng/ml; 0DEV PDGF-AB [50
ng/ml], 60.16 2.0 vs. 1DEV PDGF-AB [50 ng/ml] 26.96 5.5
ng/ml, Fig. 3B). By 5 days, PDGF concentration within culture
medium had decreased to 31.86 4.3 ng/ml in the 150 ng/ml
PDGF-AB treatment group, a decrease of 78.8% from initial
levels. Interestingly, PDGF-AB could not be detected in culture
medium taken from hMSCs treated explants (Fig. 3B) although
PDGF-AA and AB were measurable in the secretome of hMSC
when cultured independent of retinal tissue (Fig. 7G).
Adverse Effects of PDGF-AB and hMSC Treatments on
the Retina
It is worth noting that the effects of PDGF and hMSCs were
not limited to RGCs, with changes in both glial and microglia
Figure 3. Necrotic cell damage in human retinal explants over time and the detectable levels of PDGF in the culture medium. (A): Lactate
dehydrogenase within the culture medium relative to the protein content within human retinal explants treated with PDGF or hMSCs
(n5 6), *, p< .05. (B): Detection of PDGF-AB in the culture medium post addition at 0DEV (n5 6), *, p< .05 compared with 0DEV PDGF-AB
(150 ng/ml), X p< .05 compared with 0DEV PDGF-AB (50 ng/ml). Bar graphs show mean6 s.e.m with (n) number indicating the number of
unique post-mortem eyes used. The schematic in the top left shows the number of explants processed from each retina and the treatment
time course. Abbreviations: DEV, days ex vivo; MSC, mesenchymal stem cell; PDGF, platelet-derived growth factor.
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activity observed after treatments (Supporting Information
Fig. 3). 7 days after a single dose of PDGF-AB or coculture
with hMSC, extensive gliosis and inﬂammation was detectable
throughout the retina (Supporting Information Fig. 3A) with
proliferating macrophages seen within the inner retina (Sup-
porting Information Fig. 3B). Western blotting conﬁrmed GFAP
and IBA1 immunoreactivity were signiﬁcantly elevated in reti-
nal explants treated with PDGF-AB or hMSC compared with
same time point controls (GFAP, PDGF-AB [150 ng/ml]
2.56 0.3, hMSC 3.06 0.2-fold; IBA1, PDGF-AB [150 ng/ml]
1.36 0.1, hMSC 1.76 0.2-fold increase at day 5, p< .05, Sup-
porting Information Fig. 3C, 3D).
Downstream Signaling Pathway Activation Within the
Retina with PDGF-AB or hMSCs Treatments
Having shown both PDGF-AB and hMSCs offered signiﬁcant
neuroprotection to human RGCs, we investigated the activa-
tion of downstream signaling pathways shortly after each
treatment. Downstream signaling of survival pathways PI3K,
AKT, STAT3, and ERK were upregulated after 150 ng/ml PDGF-
AB or hMSC treatment versus controls at both 1 and 3 days
(PI3K 2.76 0.5 and 2.26 0.4, AKT 2.66 0.8 and 3.86 1.3,
STAT3 1.96 0.15 and 1.86 0.3, ERK 1.26 0.1 and 1.36 0.1-
fold increase at day 3, p< .05, Fig. 4A–4D) which correlated
with reduced retinal pro-apoptotic BAX expression (down
18.9%6 3.0% at 3 days compared with 3DEV Control, p< .05,
Fig. 4E). Lower concentrations of PDGF-AB showed reduced
signaling pathway activation that did not reach levels signiﬁ-
cantly different from controls (PI3K 1.86 0.6, AKT 1.86 0.5,
STAT3 1.76 0.2, ERK 1.36 0.4-fold increase at day 3, Fig. 4A–
4D). Consistent with this lack of activation was no clear reduc-
tion in BAX expression (3DEV PDGF-AB [50 ng/ml] down
6.0%6 3.2% vs. 3DEV Control, p5 .074, Fig. 4E).
Immunohistochemistry for the phosphorylated PDGF
receptors a and b (PDGFRa and b), including downstream
signaling activation, revealed similar labeling within the retina
after both PDGF-AB and hMSC treatments. Minimal receptor
phosphorylation was observed in untreated explants with lit-
tle detectable downstream signaling pathway activation (Fig.
5A–5D). In both PDGF and hMSC groups, phosphorylated
PDGFRa was detected within the RGCL and inner nuclear
layer with labeling likely along M€uller glia processes (Fig. 5A,
5B). Activated PDGFRb expression was restricted to the RGC
layer with colocalization observed with the downstream PI3K
ribosomal protein S6 kinase and phosphorylated ERK (Fig. 5C,
5D). Activated PDGFRb could be seen in TUJ11 cells indicating
a direct effect of treatments on RGCs (Supporting Information
Fig. 4A). PDGFRa activation showed no clear colocalization
with either S6 or phosphorylated STAT3 which were both acti-
vated on RGCL cells after PDGF or hMSC treatment (Fig. 5A,
5B). Total PDGF receptor expression did not differ with treat-
ment, with total PDGFRb expressed on RGC layer cells and
the occasional blood vessel within the retina. Total PDGFRa
was expressed throughout the retinal layers (Supporting Infor-
mation Fig. 4B, 4C).
Effects of Inhibiting PDGF Signaling on Retinal and
RGC Apoptosis
The impact of using a PDGF neutralizing antibody in both
PDGF and hMSC-treated explant experiments was assessed to
better understand the implications for downstream signaling
and their possible effect on retinal cell death. In PDGF-AB
treated explants, anti-PDGF treatment successfully prevented
PI3K, STAT3, and ERK signaling and removed any protective
effects on BAX expression (Fig. 6A–6D). TUJ1 expression, indic-
ative of RGC survival, was also signiﬁcantly decreased when
using the neutralizing antibody (from a 1.96 1.5-fold increase
from control using PDGF to a 1.16 0.4-fold increase from
control when adding the PDGF inhibitor, p< .05, Fig. 6E).
Selective inhibition of each signaling pathway using commer-
cially available inhibitors resulted in a slight increase in apo-
ptotic BAX expression and a modest decrease in TUJ1
expression, however less evident than with the PDGF neutral-
izing antibody (Fig. 6C, 6E).
In hMSC experiments, addition of the PDGF neutralizing
antibody to explants reduced but did not signiﬁcantly inhibit
PI3K, STAT3 and ERK signaling (Fig. 6F–6I), indicating other
secreted neurotrophin could also be stimulating these path-
ways. Some of these neurotrophin were detected in hMSC
culture medium, many of which were at higher concentrations
than PDGF (Fig. 7G). BAX and TUJ1 expression were not signif-
icantly changed with the PDGF neutralizing antibody or indi-
vidual pathway inhibition (Fig. 6H–6J). Supporting the
observation that inhibiting PDGF did not prevent hMSC
induced neuroprotection, RGC cells were quantiﬁed in
explants cocultured with hMSCs plus or minus the PDGF neu-
tralizing antibody (Fig. 7). Blocking PDGF in these experiments
had no signiﬁcant impact on RGC survival with similar cell
counts between hMSC and hMSC1 PDGF inhibitor groups
(DAPI, 78.16 7.2 vs. 68.36 2.0 cells/mm, NeuN, 33.76 5.8
vs. 32.46 1.9 cells/mm, TUJ1 24.16 2.2 vs. 23.26 1.7 cells/
mm, Fig. 7A–7C). Also, no signiﬁcant differences were identi-
ﬁed between the number of apoptotic RGCs (7DEV hMSC,
30.7%6 4.1% vs. 7DEV hMSC1 PDGF inhibitor, 41.5%6 5.2%,
p5 .172, Fig. 7D) supporting the assumption that PDGF is not
essential for hMSC mediated neuroprotection.
To ensure hMSCs remained attached to retinal explants
throughout the 7-day culture period, a selection of retinal
sections was stained with mesenchymal markers CD105 and
CD73 (Fig. 7E) which were also examined in culture prior to
transplantation (Supporting Information Fig. 1D). Both
markers detected a layer of cells on the surface of the retina
positive of mesenchymal lineage which remained viable over
the time courses investigated with little apoptotic TUNEL
staining colocalized with CD1051 (Fig. 7F).
DISCUSSION
Clinical trials into the effectiveness of MSC-based therapies
are currently underway for neuronal and [17] non-neuronal
diseases [18]. As yet, no MSC-based treatments have reached
Phase II clinical trials for glaucoma (clinicaltrials.gov) [19],
despite promising results in animal models.
The current work provides evidence that hMSC-based treat-
ments can be neuroprotective to the human retina. These
results complement previous rodent observations that both
hMSC and PDGF-AB offer robust protection in retinal explant
systems modeling axonal injury, and could offer attractive ther-
apeutic strategies. Intriguingly, in human retinas, we showed
that PDGF-AA treatment was ineffective at delaying RGC loss or
apoptosis, a difference to previous observation in rats [7]. The
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Figure 4. Activation of downstream signaling pathways in human retinal explants after a single treatment with PDGF or human MSCs.
(A–D): Activation of cell survival pathways 1 and 3 days after human explant culture in PDGF supplemented medium or addition of
hMSCs relative to untreated, same time point controls (n5 4), *, p< .05. (E): Pro-apoptotic BAX expression in treatment groups relative
to untreated, same time point controls (n5 4), *, p< .05. Bar graphs show mean6 s.e.m with (n) number indicating the number of
unique post-mortem eyes used. The schematic in the top left shows the number of explants processed from each retina and the treat-
ment time course. Abbreviations: DEV, days ex vivo; MSC, mesenchymal stem cell; PDGF, platelet-derived growth factor.
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Figure 5. PDGFR activation and downstream survival signaling could be seen within the retina and RGCL after PDGF and human MSC
treatments. (A): Increased PDGFRa signaling (purple) was observed 3 days after PDGF-AB or hMSC treatments with elevation in phos-
phorylated STAT3 (p-STAT3 - yellow) and phosphorylated S6 (p-S6 - teal) signaling in the RGCL. PDGFRb activation (purple) was detected
on RGCL cells and colocalized with activated ERK (p-ERK - yellow) or p-S6 (teal). 340 objective, scale bar5 50 mm, arrows show colocal-
ization in the RGCL. Representative images from three experimental repeats. Abbreviations: DEV, days ex vivo; MSC, mesenchymal stem
cell; PDGFR, platelet-derived growth factor receptor; RGCL, retinal ganglion cell layer.
Figure 6. The beneﬁcial effects of PDGF or human MSCs could be reduced using a variety of inhibitors when assessed 3 days after treat-
ment. (A–E): PDGF in combination with a PDGF inhibitor no longer activated survival pathways or protected against a decrease in retinal
ganglion cell (TUJ1) expression (n5 4). Inhibitors of PI3K, ERK, or STAT3 effectively blocked individual pathway signaling but did not improve
retinal (BAX) or retinal ganglion cell speciﬁc (TUJ1) survival (n5 4). (F–J): hMSCs could still offer some protection even in the presence of
inhibitors against PDGF, PI3K, ERK, or STAT3 (n5 4), *, p< .05; **, p< .01. Bar graphs show mean6 s.e.m with (n) number indicating the
number of unique post-mortem eyes used. Abbreviations: MSC, mesenchymal stem cell; PDGF, platelet-derived growth factor.
Figure 7. Inhibition of PDGF in human retinal explants cultured with human MSCs did not prevent MSC mediated neuroprotection.
(A–C): Neuronal survival in the RGCL was quantiﬁed immediately post dissection, 0DEV or after 7 days’ culture with no further medium
change (7DEV) (n5 3). (D): Number of apoptotic, NeuN1 cells were quantiﬁed and expressed as a percentage of all NeuN1 cells in the
RGC layer (n5 3). (E): Human MSCs (CD1051 - green and CD731 - red cells) could be visualized on the surface of the human retina in
close proximity to the RGC layer. (F): Human MSCs remained viable throughout the 7-day culture with little evidence of apoptotic label-
ing (red staining on green cells). (G): Multiple growth factors and neurotrophins could be measured in the hMSC secretome after 72
hours in culture. 340 objective, scale bar5 50 mm. Bar and scatter graphs show mean6 s.e.m with (n) number indicating the number
of unique post-mortem eyes used. The schematic in the top left shows the number of explants processed from each retina and the
treatment time course. Abbreviations: 0DEV, 0 days’ ex vivo; 7DEV, 7 days ex vivo; Ang, angiopoietin; EGF, epidermal growth factor; FGF,
ﬁbroblast growth factor; HGF, hepatocyte growth factor; IL, interleukin; MSC, mesenchymal stem cell; MCP, monocyte chemotactic pro-
tein; PDGF, platelet-derived growth factor; RGCL, retinal ganglion cell layer; VEGF, vascular endothelial growth factor.
isoform PDGF-AB however was strongly neuroprotective and
showed a dose dependent response when administered as a
single treatment shortly after RGC axotomy.
Regarding the discrepancy in terms PDGF isoform protec-
tion between species, it is possible that differences in the
expression pattern of PDGF receptors on rodent and human
RGCs are responsible. PDGF ligands bind two structurally
related tyrosine kinase cell surface receptors, a and b which
initiate signal induction [20, 21]. PDGF-AA exclusively binds
PDGFRa whereas PDGF-AB facilitates both PDGFRa and b
dimerization and subsequent phosphorylation.
In rats, PDGFRa phosphorylation after PDGF-AB treatment
can be detected in RGCs and M€uller glia [7, 8] implying direct
survival pathway activation occurs within the RGC layer. In
mice, PDGFRa phosphorylation after PDGF-AB treatment is
also upregulated throughout the retina [22]; however, human
PDGFRa phosphorylation is absent from RGCs. Only activated
PDGFRb was detected on human RGC signifying that
activation of the b receptor may be necessary for RGC
protection, which supports the protective effects seen with
PDGF-AB. A similar pattern of PDGFRb activation on RGCs has
been observed in mice shortly after PDGF-AB treatment,
although a direct correlation between b activation and down-
stream signaling was not explored [22].
Of the receptor isoforms, there is strong evidence linking
PDGFRb activation to enhanced neuronal survival after focal
ischemia [23, 24] and NMDA-induced cell death [25–27]. The
PDGFRb has also been shown to be involved in reducing the
progressive loss of tyrosine hydroxylase-positive neurons in
rat and human cell cultures, with PDGF-BB but not PDGF-AA
reducing neuronal damage [28]. Interestingly, PDGF-BB treated
cultures of human but not rat neurons had longer neurites
than control or PDGF-AA treated cultures [28], supporting our
observations that differences exist between species. Further-
more, knock out of PDGFRb in neurons increases their suscep-
tible to excitotoxic cell death [29].
PDGF-BB has also been shown to have comparable neuro-
protective effects to brain-derived neurotrophic factor in
human tyrosine hydroxylase-positive neurons [30] and is being
considered a clinical candidate drug for treatment of Parkin-
son’s disease after promising results in relation to restoring
dopaminergic neurotransmission and functional recovery in
vivo [31, 32]. This would be in keeping with our data sugges-
ting PDGFRb activation may provide a therapeutic target for
RGC neuroprotection. Further work using PDGF-BB, which
binds PDGFRb and not PDGFRa [33], would be useful to con-
ﬁrm the importance of each receptor in the human retina.
In addition to the beneﬁcial effect of PDGF-AB, we have
shown for the ﬁrst time that hMSCs can protect human RGC
ex vivo and mediated even stronger protection in terms of
delaying cell loss and minimizing apoptosis. After 7 days in
culture, hMSCs could completely prevent RGC loss, strength-
ening the appeal of MSC-based therapy for optic nerve dis-
eases such as glaucoma in the future. It is widely acknowledged
that MSCs do not integrate into the retina [6, 34] and, there-
fore, the observed protection relates to secreted trophic sup-
port rather than cell replacement.
Although we could detect PDGFRa and b activation fol-
lowing hMSC treatment, measured levels of secreted PDGF in
the bathing medium were low. However, assessment of the
MSC secretome in the absence of explants, via proteome
proﬁler analysis, did reveal both PDGF-AA and AB were
secreted by hMSC. Previous analysis of the hMSC secretome
has also indicated that after 3 days in culture, secreted PDGF-
AB is within the pg/ml concentration range [7], below the
detection limits of our ELISA. It is predicted that the concen-
tration of neurotrophins could be several orders of magnitude
higher at inner retinal surface if MSC and RGCs were in close
proximity. This could explain our observation of similar levels
of PDGFR activation after PDGF-AB or hMSC treatment
despite the considerable differences in quantiﬁable PDGF
within explant bathing medium. Even so, our experiments
investigating the inhibition of PDGF in human retinal explants
treated with hMSC suggests other neurotrophins are likely to
have a beneﬁcial effect on the retina and the effects of PDGF
are not exhaustive.
With regard to mechanisms of survival, many RGC neuro-
protective and regenerative strategies focus on the upregula-
tion of MTOR signaling, which is often diminished with injury
[35–37]. The mTOR signaling pathway has a pivotal role in
numerous cellular processes and can be upregulated through
elevated PI3K/AKT and MAPK/ERK signaling [37]. Activation of
mTOR activation leads to the phosphorylation of S6 and
STAT3 which have been correlated with improved RGC neuro-
nal survival, cell growth, protein synthesis and delayed apo-
ptosis [38–42]. For this reason, many RGC-based strategies
have focused on targeting one or more of these pathways
with promising outcomes on protection in models of optic
nerve injury and glaucoma [38, 43–45].
Our data showed that both PDGF and hMSC treatments
increased numerous neuroprotective pathways and the phos-
phorylation of AKT, ERK, and STAT3 inversely correlated to
apoptotic protein expression as has been observed by others
[46, 47]. It was noted that discrete pathway inhibition could
not accelerate human retinal cell apoptosis implying multiple
pathways contribute to RGC survival after injury.
Interestingly, although the extent of downstream signaling
pathway activation was comparable between PDGF and
hMSC-treated explants, overall RGC survival was greater
within the hMSC treatment group. The enhanced protection
with hMSCs is likely due to the large number of other neuro-
trophins being secreted [7, 48, 49] which could bind a larger
number of receptors present on RGCs. It was noticed that
PDGFRb was not present on all RGCs and therefore protection
could be limited to speciﬁc subtypes of RGC. Therefore, MSC
therapy may provide a more reliable treatment for diseases
of complex pathophysiology like glaucoma [50].
Potential hurdles do however exist with regard to the use
of MSCs for retinal diseases. First, it is challenging to control
the factors secreted by MSCs and how these factors could
change over time and with disease progression. Second, ques-
tions remain regarding the tumorigenic potential of such cells.
Third, MSCs also secrete factors that cause extensive reactive
gliosis [34, 51] and inﬂammation which could contribute to
retinal detachment [51, 52]. In human explants, we observed
increased microglia proliferation and gliosis after hMSC treat-
ment, similar to observations in our rodent animals models
[34, 51]. This would have serious consequences to a patient’s
vision and presents a barrier to MSC-based treatment without
suitable anti-inﬂammatory strategies. We originally hypothe-
sized that the selective use of a single growth factor would
circumvent some of these adverse effects, but PDGF led to
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similar inﬂammation and gliosis in the human retina, as
recently observed in rodents following PDGF therapy [8].
CONCLUSION
This study demonstrates that both hMSCs and PDGF have
strong neuroprotective actions and may be useful as part of a
strategy to prevent degenerative visual loss in the future if
adverse effects on retinal glia can be mitigated.
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